Severe Pediatric Onset IBD May See New Therapy Via Three-Part Venture

Severe Pediatric Onset IBD May See New Therapy Via Three-Part Venture
Medgenics recently announced a partnership with Kyowa Hakko Kirin to develop and commercialize the company’s first-in-class anti-LIGHT monoclonal antibody for severe pediatric onset inflammatory bowel disease (IBD). Plans are in the works to begin signal testing in children with the condition. Testing will occur through a joint venture that includes Dr. Robert Baldassano, Director of the Center for Pediatric IBD

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *